Duchenne News Tags: Entrada Therapeutics

On June 2, 2026, Entrada Therapeutics, Inc. shared a Community Letter for the Duchenne community outlining updates on clinical studies and more.  To view their Community Letter, please click here.

Entrada Therapeutics shared a quarterly newsletter detailing topline data from the first cohort of the ELEVATE-44-201 study, as well as updates on each of Entrada's DMD programs.

On February 26, 2026, Entrada Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted recent business updates. This full release can...

On February 17, 2026, Entrada Therapeutics, Inc. announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data from the eight patients...

On November 6, 2025, Entrada Therapeutics reported financial results for the third quarter ended September 30, 2025, and highlighted recent business updates. Please continue reading to view their full press...

On August 6, 2025, Entrada Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2025, and highlighted recent business updates. Please continue reading to view their full...

On May 28, 2025, Entrada Therapeutics, Inc. announced it has received authorization from the Health Authorities and Ethics Committees of multiple countries under the European Union Clinical Trial Regulation (EU-CTR)...

On May 8, 2025, Entrada Therapeutics reported financial results for the first quarter ended March 31, 2025, and highlighted recent business updates. Please continue reading to view their full press...

On March 24, 2025 Entrada Therapeutics Inc. announced it has received authorization from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee to initiate ELEVATE-45-201....

FDA lifts the clinical hold on ENTR-601-44 and provides authorization to initiate ELEVATE-44-102.

On February 3, 2025, Entrada Therapeutics announced it had received authorization from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee for its Clinical Trial...

Entrada announces the completion of dosing for the first and second cohorts of its Phase 1 clinical trial, ENTR-601-44-101.

Entrada reports third quarter 2023 financial results and more business updates.